Published in Nat Med on January 01, 2003
Development trends for therapeutic antibody fragments. Nat Biotechnol (2009) 3.51
Quantification of protein interactions and solution transport using high-density GMR sensor arrays. Nat Nanotechnol (2011) 2.26
Molecular imaging with nanoparticles: giant roles for dwarf actors. Histochem Cell Biol (2008) 1.73
scFv antibody: principles and clinical application. Clin Dev Immunol (2012) 1.64
Secreted Frizzled-related protein 2 as a target in antifibrotic therapeutic intervention. Am J Physiol Cell Physiol (2013) 1.62
Anchored periplasmic expression, a versatile technology for the isolation of high-affinity antibodies from Escherichia coli-expressed libraries. Proc Natl Acad Sci U S A (2004) 1.54
Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc Natl Acad Sci U S A (2006) 1.47
Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol (2006) 1.39
Inhibition of biofilm formation by monoclonal antibodies against Staphylococcus epidermidis RP62A accumulation-associated protein. Clin Diagn Lab Immunol (2005) 1.34
A new generation of protein display scaffolds for molecular recognition. Protein Sci (2006) 1.29
A modular IgG-scFv bispecific antibody topology. Protein Eng Des Sel (2009) 1.29
Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin. J Cell Biol (2008) 1.22
Metrics for antibody therapeutics development. MAbs (2010) 1.21
Development and preclinical testing of a high-affinity single-chain antibody against (+)-methamphetamine. J Pharmacol Exp Ther (2008) 1.20
Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses (2010) 1.17
Creating protein affinity reagents by combining peptide ligands on synthetic DNA scaffolds. J Am Chem Soc (2009) 1.15
The structural basis of antibody-antigen recognition. Front Immunol (2013) 1.14
Antibody-based sensors: principles, problems and potential for detection of pathogens and associated toxins. Sensors (Basel) (2009) 1.07
Molecular structures of trimeric HIV-1 Env in complex with small antibody derivatives. Proc Natl Acad Sci U S A (2012) 1.06
Isolation of alpaca anti-hapten heavy chain single domain antibodies for development of sensitive immunoassay. Anal Chem (2011) 0.97
Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct. Cancer Biother Radiopharm (2008) 0.96
Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18. Br J Pharmacol (2016) 0.91
Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT). Br J Cancer (2004) 0.89
Antibodies against G-protein coupled receptors: novel uses in screening and drug development. Comb Chem High Throughput Screen (2008) 0.89
Immuno-positron emission tomography in cancer models. Semin Nucl Med (2010) 0.88
Molecular engineering of antibodies for therapeutic and diagnostic purposes. MAbs (2012) 0.87
Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer. Expert Opin Drug Deliv (2014) 0.85
Isolation and characterization of antibody fragments selective for specific protein morphologies from nanogram antigen samples. Biotechnol Prog (2013) 0.85
Rational conversion of affinity reagents into label-free sensors for Peptide motifs by designed allostery. ACS Chem Biol (2010) 0.85
Designing immunotherapies to thwart drug abuse. Mol Interv (2009) 0.85
Targeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: crossing the blood-brain barrier divide. Expert Opin Drug Deliv (2013) 0.85
Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitors. Biomed Res Int (2013) 0.84
Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus. J Infect Dis (2016) 0.83
Molecular targeting of angiogenesis for imaging and therapy. Eur J Nucl Med Mol Imaging (2004) 0.82
Discovery of hapten-specific scFv from a phage display library and applications for HER2-positive tumor imaging. Bioconjug Chem (2014) 0.82
In situ recognition of cell-surface glycans and targeted imaging of cancer cells. Sci Rep (2013) 0.81
Nanoparticle targeting to diseased vasculature for imaging and therapy. Nanomedicine (2014) 0.81
Functional expression of a single-chain antibody fragment against human epidermal growth factor receptor 2 (HER2) in Escherichia coli. J Ind Microbiol Biotechnol (2014) 0.80
Preparation and functional studies of hydroxyethyl chitosan nanoparticles loaded with anti-human death receptor 5 single-chain antibody. Onco Targets Ther (2014) 0.80
Strategies to stabilize compact folding and minimize aggregation of antibody-based fragments. Adv Biosci Biotechnol (2013) 0.79
Customizing monoclonal antibodies for the treatment of methamphetamine abuse: current and future applications. Adv Pharmacol (2014) 0.79
Monoclonal antibodies for podocytopathies: rationale and clinical responses. Nat Rev Nephrol (2009) 0.79
Modification of the loops in the ligand-binding site turns avidin into a steroid-binding protein. BMC Biotechnol (2011) 0.79
Phage display approaches for the isolation of monoclonal antibodies against dengue virus envelope domain III from human and mouse derived libraries. Int J Mol Sci (2012) 0.79
Directed evolution of human heavy chain variable domain (VH) using in vivo protein fitness filter. PLoS One (2014) 0.78
Human TNF cytokine neutralization with a vNAR from Heterodontus francisci shark: a potential therapeutic use. MAbs (2012) 0.77
Blocking monocyte transmigration in in vitro system by a human antibody scFv anti-CD99. Efficient large scale purification from periplasmic inclusion bodies in E. coli expression system. J Immunol Methods (2014) 0.77
Optimal Neutralization of Centruroides noxius Venom Is Understood through a Structural Complex between Two Antibody Fragments and the Cn2 Toxin. J Biol Chem (2015) 0.77
Immunotoxins: a review of their use in cancer treatment. J Stem Cells Regen Med (2006) 0.77
Gene-based antibody strategies for prion diseases. Int J Cell Biol (2013) 0.77
Structural characterization of a therapeutic anti-methamphetamine antibody fragment: oligomerization and binding of active metabolites. PLoS One (2013) 0.76
Development and characterization of recombinant antibody fragments that recognize and neutralize in vitro Stx2 toxin from Shiga toxin-producing Escherichia coli. PLoS One (2015) 0.76
Antibody Engineering for Pursuing a Healthier Future. Front Microbiol (2017) 0.75
Cross-neutralizing anti-HIV-1 human single chain variable fragments(scFvs) against CD4 binding site and N332 glycan identified from a recombinant phage library. Sci Rep (2017) 0.75
Engineering tandem single-chain Fv as cell surface reporters with enhanced properties of fluorescence detection. Protein Eng Des Sel (2015) 0.75
The Efficacy of Humanized Antibody against the Sporothrix Antigen, gp70, in Promoting Phagocytosis and Reducing Disease Burden. Front Microbiol (2017) 0.75
Generation and in vivo characterization of a chimeric αvβ5-targeting antibody 14C5 and its derivatives. EJNMMI Res (2013) 0.75
Rapid discovery and optimization of therapeutic antibodies against emerging infectious diseases. Protein Eng Des Sel (2008) 0.75
Role of the N-terminus of epidermal growth factor in ErbB-2/ErbB-3 binding studied by phage display. Biochemistry (2002) 0.76